Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the PK properties, tolerability, and safety of lorcaserin HCL (BELVIQ) in obese adolescent subjects between the ages of 12 to 17 years old
Full description
The purpose is to:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Adolescent subjects aged 12 to 17 years, inclusive at screening
a. Eligible female subjects who are sexually active will be:
BMI ≥ 95th percentile for age and gender, but ≤ 44 kg/m21
Considered to be in stable health in the opinion of the Investigator.
Parent or guardian who can sign written informed consent and subject willing to sign assent
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
8 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal